<DOC>
	<DOCNO>NCT01025154</DOCNO>
	<brief_summary>The goal clinical research study learn combination clofarabine , cytarabine , idarubicin help control Acute Myeloid Leukemia ( AML ) patient age 18 60 year old . The safety study drug combination also study .</brief_summary>
	<brief_title>Clofarabine , Idarubicin , Cytarabine Combination Acute Myeloid Leukemia ( AML ) Induction</brief_title>
	<detailed_description>The Study Drugs : Clofarabine design interfere growth development cancer cell . Idarubicin design cause break DNA ( genetic material cell ) cancer cell interfere growth development . Cytarabine design insert DNA cancer cell stop DNA repairing . Study Drug Administration : If find eligible take part study , receive study drug combination 1 2 `` Induction Cycles '' treatment . Whether receive second Induction Cycle depend disease 's response first Induction Cycle . Each Induction Cycle last 4-6 week , depend reaction study drug . During Induction Cycle , receive study drug follow schedule : - Clofarabine , vein , 1-2 hour Days 1-5 . - Cytarabine , vein , 2-3 hour Days 1-5 . - Idarubicin , vein , 30-60 minute Days 1-3 . If disease show response treatment Induction Cycle ( ) , may continue receive 6 `` Consolidation Cycles '' treatment . Each Consolidation Cycle last 3-10 week , depend reaction study drug . During Consolidation Cycle , receive study drug follow schedule : - Clofarabine , vein , 1-2 hour Days 1-3 . - Cytarabine , vein , 2-3 hour Days 1-3 . - Idarubicin , vein , 30-60 minute Days 1-2 . Study Visits : On Day 1 every cycle : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1-2 teaspoon ) draw routine test . Throughout study , blood bone marrow test check status disease help doctor decide need additional cycle treatment . Blood ( 1-2 tablespoon time ) drawn 2 time week routine test Induction Cycles . This blood also draw every week Consolidation Cycles . About 3 week first receive study drug , bone marrow aspirate check status disease . After , bone marrow aspirate every 2 week ( often doctor think need ) . However , routine blood test show still leukemia present , bone marrow sample may need collect . You need stay Houston first 5 week treatment . After , need return Houston receive treatment , check-up visit blood test local doctor treatment . Length Study : You able receive study drug 8 cycle ( maximum 2 induction cycle 6 consolidation cycle ) . You take study disease get bad experience intolerable side effect . Follow-up Scan : Within 8 week stop take study drug , echocardiogram Multiple gate acquisition scan ( MUGA ) scan check heart function . This investigational study . Cytarabine idarubicin FDA approve commercially available treatment patient AML . Clofarabine FDA approve commercially available treatment patient acute lymphoblastic leukemia ( ALL ) . The use drug combination treatment AML investigational . Up 60 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Diagnosis AML ( World Health Organization ( WHO ) classification ) 2 . Patients must chemotherapynaïve , i.e . receive prior cytotoxic chemotherapy AML ( exception hydroxyurea ) . They could receive prior therapy hypomethylating agent , target , biological agent . 3 . Age 18 60 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 5 . Serum creatinine &lt; /= 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73m^2 calculate Modification Diet Renal Disease equation Predicted GFR ( ml/min/1.73m^2 ) =186 * ( serum creatinine ) ^1.154 x ( age year ) ^0.023 * ( 0.742 patient female ) * ( 1.212 patient black ) , SCr serum creatinine measure mg/dL . serum bilirubin &lt; /= 1.5 * upper limit normal ( ULN ) ( unless increase due hemolysis congenital disorder ) ; serum transaminase ( SGPT and/or SGOT ) &lt; /= 2.5 * ULN . 6 . Cardiac ejection fraction &gt; /= 45 % ( either echocardiography MUGA scan ) . 7 . Ability understand provide sign informed consent . 1 . Patients acute promyelocytic leukemia ( APL ) . 2 . Any coexist medical condition judgment treat physician likely interfere study procedure result . 3 . Nursing woman , woman childbearing potential positive urine pregnancy test , woman childbearing potential willing maintain adequate contraception ( birth control pill , intrauterine device ( IUD ) , diaphragm , abstinence , condom partner ) entire course therapy . 4 . Active uncontrolled infection require therapy IV antibiotic antifungal therapy . Prior concurrent history one opportunistic infection ( e.g. , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>chemotherapy-naïve</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
</DOC>